Founded in 1992, Hualan Biological Engineering Inc. (Hualan Bio) is a key National high-tech biopharmaceutical company in China engaging in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics. Hualan Bio was the first company whose plasma products gained GMP certificate in China, the first listed company of plasma products, the first H1N1 Influenza Vaccine manufacturer in the whole world, the first influenza vaccine manufacturer passing WHO-PQ in China. Passing "ISO9000" (quality), "ISO14000" (environment) and "GBT28000" (occupational health) management system certification.
As a major manufacturer for the plasma products and vaccines designated by national authorities, Hualan Bio is the largest manufacturer and provider for both plasma products and influenza vaccines in Asia. Hualan Bio is the leading company which has integrated the innovative R & D activities, state-of the-art technologies, scientific management styles and high standard quality control and assurance systems in China. The company has been undertaking research projects from national, provincial and municipal organizations. In 2010, Hualan Bio formed a strategic alliance with the Chinese Academy of Sciences (CAS) and collaborates with several institutes for the discovery of innovative biologics. Recently, the R & D center at Hualan Bio was recognized as one of the National High-tech Center in China, which built the solid foundation for the development of novel products and future growth.
Driven by the mission “Dedicating for Human Healthcare”, Hualan Bio has made a significant effort and successfully developed and manufactured a number of products such as human Albumin, IVIG, PCC, Fibrin Sealant, Factor VIII, Seasonal Influenza Vaccine, H1N1 Vaccine, ACYW135 Meningococcal Polysaccharide Vaccine, and Hepatitis B Vaccine, which can be classified into 3 categories, 14 products, and 50 formulations. As an example, during the breakout of the H1N1 pandemic in 2009, Hualan Bio was the first to manufacture and market the H1N1 vaccine with the best quality, which has a great impact on the human life and social stability.
Since the startup over 25 years ago, Hualan Bio has been one of the fastest growing biopharmaceutical companies in China. The company went through rapid growth and expansion and owns twenty-eight wholly-owned or mainly-controlled subsidiaries across overall China. With the growth, quality, and responsibility, and innovation, Hualan Bio has evolved into a leading research-based biopharmaceutical company, and earned a well-recognized brand name in China.